• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Publication
Peer-Reviewed
Evidence-Based OncologyJanuary 2021
Volume 27
Issue 1

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

eAPPENDIX Clinical and Economic Burden of Intravenous Paclitaxel
Articles in this issue
Evidence-Based Oncology
ASH 2020: Clinical Updates
ASH 2020: COVID-19 and Hematology
ASH 2020: COVID-19 and Hematology
ASH 2020: CAR T-Cell Therapy Updates
ASH 2020: CAR T-Cell Therapy Updates
ASH 2020: The Next Wave
ASH 2020: The Next Wave
Evidence-Based Oncology
2020 SABCS: Topics in Precision Oncology
Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
evidence-based oncology
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Evidence-Based Oncology
Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Evidence-Based Oncology
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Related Videos
Dr Debra Patt
Dr Debra Patt
Dr Yara Abdou
Adam Brufsky, MD, PhD, University of Pittsburgh
Dr Steven Manobianco
Dr Amrita Basu
Dr Adam Brufsky
Related Content
Our key takeaways from SABCS 2025 range from camizestrant and T-DXd data to menopause care and alcohol-related breast cancer risk.

ICYMI: Highlights From SABCS 2025

December 29th 2025
Article

New therapies and individualized care plans for menopausal women highlighted the most-read 2025 SABCS coverage.

Read More

Age-Related Disparities in ADC Treatment Rates in Breast Cancer: Tabby Khan, MD

Age-Related Disparities in ADC Treatment Rates in Breast Cancer: Tabby Khan, MD

October 31st 2025
Podcast

A new analysis from Komodo Health pinpointed significant disparities by age and insurance in antibody-drug conjugate (ADC) treatment rates for metastatic breast cancer.

Listen

The FDA approved the HER2-directed DXd antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki, for patients with unresectable or metastatic HER2-positive breast cancer. | Image Credit: aznan - stock.adobe.com .jpeg

FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer

December 15th 2025
Article

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

Read More

The Evolution of AI Models in Mammography With Robert Nishikawa, PhD

The Evolution of AI Models in Mammography With Robert Nishikawa, PhD

October 23rd 2025
Podcast

AI-powered mammography is enhancing breast cancer screening and early detection through cutting-edge radiology insights.

Listen

AI and digital health are redefining what’s possible in breast cancer treatment. | Image Credit: @PajarosVolando-adobe.stock.jpeg

5 AI and Digital Health Advances Transforming Breast Cancer Care and Research

November 14th 2025
Article

AI and digital tools are reshaping breast cancer care—from screening and trials to remote monitoring and lifestyle support.

Read More

Breast Cancer Dominating Oncology Research, Access Disparities: Gen Li, PhD

Breast Cancer Dominating Oncology Research, Access Disparities: Gen Li, PhD

November 3rd 2025
Article

Breast cancer is the most researched disease globally, yet there are still significant gaps in equity and access to care and treatments.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.